

New Insights into Atopic Dermatitis: Role of Skin Barrier and Immune Dysregulation

Donald YM Leung¹

ABSTRACT

Atopic dermatitis (AD) is a chronic inflammatory skin disease that is often associated with the development of food allergy and asthma. New insights into AD reveals an important role for structural abnormalities in the epidermis resulting in a leaky epithelial barrier as well as chronic immune activation that contribute to the pathophysiology of this common skin disease. Patients with AD have a predisposition to colonization or infection by microbial organisms, most notably *Staphylococcus aureus* and herpes simplex virus (HSV). Measures directed at healing and protecting the skin barrier and controlling the immune activation are needed for effective management of AD. Early intervention may improve outcomes for AD as well as reduce the systemic allergen sensitization that may lead to associated allergic diseases in other organs.

KEY WORDS

atopic dermatitis, eczema, immune, infection, skin barrier

INTRODUCTION

AD is a common chronic inflammatory skin disease that is often associated with the development of food allergy and asthma.¹ Recent studies reveal strong associations between mental health disorders and AD, suggesting the need to effectively manage this disease for patient's general well being.^{2,3} Lifetime prevalence of AD varies worldwide from approximately 8-18%.⁴ A recent report in Shanghai, China reported that the prevalence of AD was significantly higher in urban areas of Shanghai compared to rural areas of this city.⁵ Life style and environmental factors likely contribute to clinical expression in AD.^{6,9} In Japan, environmental oxidants have been implicated in the changing prevalence of AD.¹⁰ Stress, such as experienced by patients during the Great Hanshin earthquake, has also been well documented to exacerbate AD.¹¹

The skin is an important interface between the host and its environment. A leaky skin epithelial barrier combined with abnormal immune responsiveness likely contributes to the pathophysiology of AD.^{12,13} The current review will highlight recent insights into the role of skin barrier, environmental factors and im-

mune dysfunction leading to AD. The effective treatment of AD requires a multi-pronged approach involving skin barrier repair, control of skin inflammation, identification and management of allergenic triggers, as well as treatment of microbial infection.¹⁴

CLINICAL FEATURES AND PHENOTYPES OF AD

New insights into mechanisms of AD should address the key clinical features of AD as well as explain the different phenotypes associated with this skin disease.¹⁵ The cardinal feature of AD is severe pruritus that is associated with cutaneous hyperreactivity to various environmental stimuli including exposure to food and inhalant allergens, irritants, changes in physical environment (including pollution, humidity, etc), microbial infection and stress. After patients scratch their skin, an acute eczematoid eruption (with erythematous papules) appears, and lichenification with epidermal hyperplasia results from chronic eczema. This is in contrast to patients with chronic idiopathic urticaria that develop hives but not eczema after scratching, and highlights potential differences in mechanisms between chronic idiopathic urticaria (e.g. autoantigen induced mast cell degranulation

¹Division of Pediatric Allergy-Immunology, Department of Pediatrics, National Jewish Health, Denver, CO, USA.

Conflict of interest: No potential conflict of interest was disclosed.

Correspondence: Donald YM Leung, MD, PhD, National Jewish

Health, 1400 Jackson Street, Denver, CO 80206, USA.

Email: leungd@njhealth.org

Received 27 March 2013.

©2013 Japanese Society of Allergology

Table 1 Different phenotypes of atopic dermatitis

Early onset vs late onset
Mild vs severe eczema
Increased IgE vs non-atopic
<i>S. aureus</i> infection/colonization
Disseminated viral or fungal infections e.g. EH, molluscum contagiosum, Malassezia
The atopic march

without skin barrier dysfunction) as opposed to AD which stems from skin barrier dysfunction, and increased penetration of antigens which drive mononuclear cell infiltration and chronic skin inflammation.¹⁶

Multiple overlapping, but distinct, clinical phenotypes of AD exist (Table 1). Most infants who present with mild AD will outgrow their skin disease in later childhood. However, a group of difficult to manage patients exist who have early onset eczema, with severe life long AD. Adult onset AD also exist although it is unclear whether these may be patients that had eczema during infancy, then went into a prolonged remission only to have relapse of eczema later in life since recall history, in such cases, may not be reliable. Over 50% but certainly not all AD have associated asthma, allergic rhinitis or food allergy. Approximately 80% of AD patients have elevated serum IgE and/or immediate skin test reactivity to allergens but 20% of AD have no IgE to food or inhalant allergens. However, it is possible that such intrinsic or non-atopic patients may have IgE or autoreactive T cells to autoallergens or microbial antigens which are not routinely measured.¹⁷⁻²⁰ Other AD subsets exist including those who are prone to skin infection such as *Staphylococcus aureus* skin infections or eczema herpeticum.^{21,22} Although up to 90% of AD may have problems with *S. aureus* skin colonization, actual overt skin infections requiring systemic antibiotic treatment affect less than 50% of AD. Less than 5% of AD are predisposed to eczema herpeticum or eczema vaccinatum.²³ These different phenotypes likely arise from a complex combination of mutations and epigenetic effects on genes controlling protein expression in the skin barrier, innate and adaptive immune response with a strong environmental influence.

EPITHELIAL SKIN BARRIER ABNORMALITIES IN AD

Multi-Functional Role of Filaggrin

The skin barrier plays a critical role in host defense against microbial invasion, and allergen penetration. The stratum corneum represents the culmination of a complex epithelial cell differentiation process in which keratinocytes produce a strong but resilient physical barrier of cross-linked matrix containing lipids and proteins which minimize water loss and protects the body from allergen or microbial penetration.

Recent studies indicate that defects in epidermal barrier function contribute greatly to triggering and perpetuation of skin inflammation in AD.^{12,13} The skin in AD is characterized by increased transepidermal water loss, and a defect in terminal keratinocyte differentiation leading to reduced levels of ceramides, filaggrin and antimicrobial peptides.²⁴⁻²⁹ Concomitantly increased protease activity and proinflammatory cytokine release resulting from increased endogenous keratinocyte and mast derived proteases released in atopic skin as well as exogenous proteases from environmental allergens, such as dust mites, or *S. aureus* results in skin barrier breakdown.^{30,31}

In normal subjects, formation of the cornified cell envelope involves dephosphorylation and cleavage of profilaggrin by serine proteases ending in the release of filaggrin.¹³ Filaggrin aggregates the keratin cytoskeleton to facilitate the flattening of keratinocytes in the outermost skin layer. Additionally, other proteins encoded by genes in the epidermal differentiation complex including loricrin and involucrin are essential components of the epidermal barrier.³² As the water content of the stratum corneum drops, filaggrin is proteolyzed into pyrrolidine carboxylic acid and trans-urocanic acid which contribute to the composition of natural moisturizing factor (NMF) and accounts in part for corneocyte hydration.³³ Filaggrin deficiency in AD contributes to decreased hydration of the stratum corneum and increased transepidermal water loss.³⁴

Importantly, filaggrin breakdown products play an important role in acidifying the stratum corneum and decreased generation of filaggrin metabolites increases the pH of the stratum corneum leading to activation of a number of serine proteases and may thereby increase barrier breakdown.³⁵ A recent *in vitro* study demonstrated that *S. aureus* growth rate and cell density were affected by the acidic filaggrin breakdown products urocanic acid and pyrrolidone carboxylic acid.³⁶ Lower pH was associated with reduced expression of secreted and cell wall-associated proteins, including proteins involved in *S. aureus* adherence to the skin such as clumping factor B and fibronectin binding protein A, as well as protein A, which is involved in immune evasion.

The critical role of skin barrier dysfunction as a causative factor in AD is supported by reports demonstrating that loss-of-function mutations in the filaggrin gene (FLG) are the most significant and well replicated risk factor for development of AD.^{13,37} FLG mutations increase the risk for persistent dry skin,³⁸ enhance percutaneous immune responses³⁹ and is associated with increased expression of IL-1 in the stratum corneum of patients with AD.⁴⁰ Filaggrin has also been found to protect against staphylococcal alpha toxin mediated keratinocyte cell death.⁴¹ The skin barrier abnormality caused by FLG mutations is also associated with increased serum 25-hydroxy vita-




Fig. 1 Immunologic pathways involved in different phases of atopic dermatitis. Published with permission from: Gittler JK, Shemer A, Suárez-Fariñas M, *et al.* Progressive activation of T_H2/T_H22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. *J Allergy Clin Immunol* 2012; 130: 1344-54.

min D concentrations.⁴²

Filaggrin null mutations affect a minority of subjects with AD. Reduction in filaggrin are often observed even in the skin of AD patients who have no detectable FLG null mutations. In this regard, intragenic copy number variation within the filaggrin gene has been demonstrated to contribute to the risk of AD with a dose-dependent effect.⁴³ Furthermore, a variety of cytokines have been found to reduce filaggrin expression including IL-4, IL-13, TNF and IL-25.⁴⁴⁻⁴⁶ Proteomic profiling of AD skin have revealed found that multiple other proteins related to the skin barrier (filaggrin-2, corneodesmosin, desmoglein-1, desmocollin-1, and transglutaminase-3) and generation of natural moisturizing factor (arginase-1, caspase-14, and gamma-glutamyl cyclotransferase) were expressed at significantly lower levels in lesional, as compared to nonlesional, sites of patients with AD.²⁴ These studies are supported by genomic and histologic profiling studies of AD skin revealing broad termination epidermal differentiation defects.²⁹ Thus, a combination of genetic and acquired factors contribute to reduced epidermal differentiation, and

downregulation of epidermal barrier function.

Tight Junction Abnormalities: A Second Defect in the Physical Barrier of AD

Gene expression profiling of nonlesional epithelium from patients with extrinsic AD, nonatopic subjects, and patients with psoriasis recently revealed a strikingly lower level of the tight junction proteins, claudin-1 and claudin-23, in patients with AD.⁴⁷ Tight junctions are found on opposing membranes of stratum granulosum keratinocytes directly below the stratum corneum and thereby form a second physical barrier in the epidermis (Fig.1). They are made up of a complex of adhesive proteins that control the passage of fluids and solutes through the paracellular pathway. The nonlesional epithelium of AD subjects has been shown to have bioelectric abnormalities indicative of a tight junction defect which could be the consequence of reduced levels of claudin-1 (CLDN1), a key tight junction adhesive protein.⁴⁷ This is consistent with earlier work in CLDN1 knockout mice that established the importance of epidermal tight junctions and claudin-1. CLDN1 knockout mice died

within 24 hours of birth with severe dehydration and increased epidermal permeability as measured by dye studies and transepidermal water loss.⁴⁸ The susceptibility of human keratinocytes to HSV-1 infection is inversely related to the degree of cell-cell contact and confluency maintained by claudin-1 levels.⁴⁹ In AD, an inverse correlation was found between CLDN1 expression and markers of Th2 polarity (total eosinophil counts and serum total IgE).

IMMUNE RESPONSES IN AD

Once the 2 physical barriers (filaggrin, tight junctions) are breached, a rapid, innate immune response must be initiated to prevent further microbial invasion and replication. Keratinocytes and antigen presenting cells in the skin express a number of innate immune receptors also referred to as pattern recognition receptors of which Toll like receptors (TLRs) are the best known.^{12,50} Stimulation of TLRs by microbes or tissue injury leads to release of antimicrobial peptides, cytokines and chemokines and enhanced strength of TJs to limit penetration of allergens and microbes. Patients with AD have been found to have reduced TLR function. Studies of patients with AD reveal that they are deficient in their production of keratinocyte derived antimicrobial peptides needed to control *S. aureus* and viral replication.¹² This may predispose to microbial colonization and chronic skin inflammation.

The adaptive immune response in AD is associated with increased expression of the Th2 cytokines (IL-4, IL-13 and IL-31) and the Th22 cytokine, IL-22⁵¹ during the acute phase of AD (Fig. 1). These cytokines reduce epidermal differentiation and thereby contribute to reduced filaggrin expression and anti-microbial peptide expression. IL-31 induces severe pruritus in addition to its inhibitory effects on epidermal differentiation.⁵² The complex cytokine profile that evolves after formation of acute AD lesions, includes a rise in interferon-gamma which induces apoptosis of keratinocytes.⁵³ These effects, however, can be counterbalanced by IL-10 which controls dendritic cell induced T cell reactivity in the skin.^{54,55} Corticotropin-releasing hormone (CRH) has recently been found to downregulate IL-10 production by adaptive forkhead box protein 3-negative regulatory T cells in AD.^{56,57}

Although AD is known as a Th2- and Th22 mediated inflammatory skin disease whereas psoriasis is known as a Th1/Th17 mediated skin disease,⁵⁸ there may be other AD subsets. Indeed, IL-17 expression has been reported in mouse models of eczema.⁵⁹ Recently, a comparative transcriptomic analyses of AD and psoriasis revealed evidence for increased IL-17 gene expression and shared neutrophilic inflammation in these two skin diseases.⁶⁰

Dendritic cells are recognized as one of the key cells involved in the initiation of T cell responses in various skin diseases.⁶¹ In AD, dendritic cells such as

Langerhans cells and inflammatory dendritic epidermal cells express increased levels of FcεRI as well as reduced interferon responses.⁶² Blocking H1 histamine receptor signaling of dendritic cells dampened allergen driven skin immune responses.⁶³ Epidermal keratinocytes in AD express increased thymic stromal lymphopoietin (TSLP), a cytokine that enhances dendritic cell driven Th2 cell differentiation.^{64,65} IL-25 and IL-33, released from multiple cell types including keratinocytes and type 2 innate lymphoid cells, also augment Th2 responses and can activate eosinophils and mast cells.⁶⁶ Mechanical injury, allergen exposure and microbial infection increases TSLP, IL-25 and IL-33 thus increasing Th2 responses.^{67,68}

A critical link between the barrier defect in AD patients with *FLG* mutations and Th2 polarization can be explained by enhanced allergen penetration through the damaged epidermis accompanied by increased production of TSLP, IL-25 and IL-33 by keratinocytes and other skin cells leading to a Th2-type milieu. TSLP, in particular, may act as a “master switch” for allergic inflammation since it has effects on a number of key cells involved in cutaneous allergic inflammation, including mast cells, basophils and eosinophils.⁶⁴ The clinical observation that topical calcineurin inhibitors and topical corticosteroids can partially correct the barrier defect in AD supports the concept that inflammation or immune activation can downregulate the barrier function in AD and that there is cross talk between the epidermal barrier and the immune system.⁶⁹

DEFINING AD SUBSETS FOR BETTER MANAGEMENT APPROACHES

Recent advances in the genetics and pathophysiology of AD have contributed to our understanding of endotypes in AD.¹⁵ Endotypes have been proposed in asthma which is recognized to be a complex disease or syndrome that can be divided into distinct disease entities based on distinct pathophysiological mechanisms, referred to as “asthma endotypes”.⁷⁰ The importance of eventually defining endotypes in AD is that these new subtypes can be used in clinical study design and drug development to target existing and novel therapies to patients most likely to benefit from a mechanism-based treatment. In the future, AD may be characterized by genotype, biomarkers reflecting immune polarization and the clinical phenotype.

Multiple clinical phenotypes have been described in AD (Table 1). Childhood AD is common, with more than 60% of patients having onset of disease within the first 2 years of age.⁷¹ Complete clearance of childhood AD occurs in approximately 50% of patients. The remainder have recurrences in adolescence and adulthood. Adult onset of AD can also occur without a history of childhood AD.⁷² In all forms of AD, clinical phenotypes can be further stratified according to mild vs severe forms and their various trig-

Atopic Dermatitis

AD _{FLG}	Clinical Features	Biophysical Features
	Palmar Hyperlinearity	Severe Decrease in Natural Moisturizing Factor (NMF)
	More Persistent	↑pH
	↑Allergic Sensitization	↑IL-1β
	↑Risk of Asthma	
	↑Severity	
	↑Eczema Herpeticum	
AD _{NON-FLG}	Clinical Features	Biophysical Features
	No Palmar Hyperlinearity	Mild Decrease in Natural Moisturizing Factor (NMF)
	Less Persistent	pH Lower Compared to AD _{FLG}
	Less Allergic Sensitization	IL-1β Low Compared to AD _{FLG}
	Lower Risk of Asthma	

Fig. 2 Comparison of clinical and biophysical features of atopic dermatitis patients with (AD_{FLG}) and without (AD_{NON-FLG}) filaggrin mutations. Published with permission from: McAleer MA, Irvine AD. The multifunctional role of filaggrin in allergic skin disease. *J Allergy Clin Immunol* 2013; 131: 280-91.

gers including bacterial and viral infection. There has also been considerable interest in the group who undergo the atopic march which refers to AD patients with associated food allergy who develop asthma or allergic rhinitis later in childhood as this provides an opportunity to develop preventative approaches to prevent respiratory allergy. High systemic sensitization to food and inhalant allergens may occur in AD due to penetration of these environmental allergens through the damaged skin barrier of these patients.

Genetic studies have revealed the association of mutations which are beginning to distinguish certain endotypes of AD. The strongest data involves identification of patients with filaggrin mutations.¹³ AD patients with homozygous filaggrin null mutations or compound heterozygotes, as compared to patients with normal filaggrin gene expression, have early onset of skin disease, more persistent, and severe eczema which can be complicated by eczema herpeticum^{13,73} (Fig. 2). They also often have palmar hyperlinearity, greater risk of allergen sensitization, a history of food allergy and develop asthma.^{74,75} These patients also have an increased pH in their stratum corneum which may predispose them to *S. aureus* colonization.³⁶ Patients who have heterozygous filaggrin mutations have an intermediate phenotype.

Although filaggrin mutations are the most significant and well replicated genetic mutation associated with AD, filaggrin mutations account for only a minority of total AD although up to 50% of severe AD can have filaggrin mutations.¹³ Many other genes involving skin barrier responses as well as the innate and adaptive immune response have also been implicated reinforcing the concept that AD is a complex genetic disease.^{15,76-78} These include various genes controlling skin barrier function such as mutations in the serine protease inhibitor Kazal-type 5 (SPINK5) gene, which encodes the protease inhibitor lymphoepithelial Kazal-type-related inhibitor (LEKTI).⁷⁹ In a murine model of AD generated by epidermal LEKTI deficiency,⁸⁰ severe eczema and increased TSLP production was observed mimicking some of the critical features in AD. Genetic variants in CLDN1 are also associated with risk of eczema herpeticum in AD subjects.⁴⁹ Furthermore, excluding subjects with a FLG mutation strengthened the association of CLDN1 mutations with susceptibility to EH. These data suggest that both stratum corneum and TJ epidermal barrier defects participate in mechanisms that increase the susceptibility of subjects with ADEH+ to widespread cutaneous infections with HSV.

Gene variants may also contribute to the abnormal




Fig. 3 Stepwise approach for management of AD according to disease severity.

innate immune response and Th2 adaptive responses found in AD. These include the observation that certain Toll-like receptor 2 (TLR2) variants are associated with severe AD.⁸¹ A recent study found an increased association between genes encoding TSLP and its receptors, IL7R, with risk of eczema herpeticum.⁸² Association between gene variants encoding for the Th2-driving cytokines IL-4⁸³ and IL-13,⁸⁴ and the down-stream transcription factor STAT6⁸⁵ support the importance of Th2 responses in AD. A common haplotype encoding IL-31, a cytokine which induces severe pruritus, has been reported to be associated with the intrinsic/non-IgE-associated form of AD.⁸⁶ These findings point to the importance of both barrier and immune response genes in driving the complex phenotype of AD.

Given the complex genetic picture of AD, the development of biomarkers is important to assess the final immune polarized pathways that may exist in various AD subsets. The best biomarkers for AD currently define patients who are Th2 polarized vs those who are not. Approximately 80% of AD have elevated serum IgE levels. These patients often have increased eosinophilia and serum levels of the Th2 chemokine, thymus and activation regulated chemokine (TARC) levels. Additional markers are needed to better monitor AD patients with so-called intrinsic AD. It is noteworthy, however, that studies of so-called intrinsic AD patients who lacked IgE to conventional inhalant and food allergens did have de-

tectable serum IgE to autoantigens in the skin and microbial antigens from bacterial and fungi that colonize the skin.^{19,87} Therefore a wider range of IgE screens to various exogenous and endogenous antigens is warranted to determine potential triggers of AD as it may have an important impact on pathways triggering allergic skin inflammation. Overall the various causes of a leaky epithelial skin barrier leading to disruption of the microbial flora, a defective innate immune response and enhanced Th2 adaptive immune abnormalities that influences the physical barrier provides some explanation for the different AD subsets leading to complex clinical phenotypes.

TREATMENT AND MANAGEMENT OF AD

The management of AD requires a systematic, multi-pronged approach. This includes skin hydration and barrier repair, topical anti-inflammatory medications, control of infection and elimination of exacerbating factors (including allergens, irritants and emotional triggers) taking into consideration that AD is a heterogeneous disease requiring an individualized approach for each patient. Treatment should utilize a stepwise approach that is dependent on the severity of skin disease (reviewed in reference 14).

The first step in AD is reduced skin barrier function resulting from lack of structural proteins and lipids in the epidermis (Fig. 3). This leads to enhanced water loss and dry skin. Except for the mildest cases, skin hydration will often require warm soaking baths

for at least 10 minutes followed by the application of a moisturizer. Moisturizers, available in the form of creams, and ointments should be recommended as first-line therapy. When using the more occlusive ointments, consider pre-wetting the skin before its application. In patients with moderate to severe AD, ceramide rich or filaggrin containing creams may be considered.

The second step in AD is skin inflammation. This is invariably present in patients with moderate to severe AD, even involving their non-lesional skin, since a defective barrier allows allergens and microbes to penetrate the skin thereby triggering the immune and inflammatory response. In AD that is not controlled by emollients alone, a topical anti-inflammatory agent should be used. Low-potency corticosteroids are recommended for maintenance therapy, whereas medium and high-potency corticosteroids should be used for the treatment of clinical exacerbation over short periods of time. Proactive treatment with intermittent medium potency topical steroids and calcineurin inhibitors have been shown to reduce AD relapses.⁸⁸

Jensen *et al.*⁶⁹ looked at transdermal water loss, as well as several other parameters of epidermal barrier including stratum corneum hydration and dye penetration and showed improvement in all parameters when AD patients were treated with both a topical steroid and a topical calcineurin inhibitor. Both treatments normalized markers of epidermal cell differentiation. Of note, while expression of filaggrin was reduced in untreated patients with AD, it was completely restored on treatment with either anti-inflammatory therapy. Coal tar, which has weaker anti-inflammatory effects has also been shown to improve skin barrier in AD.⁸⁹

Another important long-term strategy for patient management is the identification of factors that trigger AD including foods (particularly in infants and young children), aeroallergens, stress and infection. Patients with AD have a unique propensity to be colonized or infected by a number of microbial organisms.¹ To assess the relationship between skin microbiota and disease progression, Kong *et al.*⁹⁰ recently performed 16S ribosomal RNA bacterial gene sequencing on DNA from serial skin sampling of children with AD. In AD, the proportion of *Staphylococcus* sequences, particularly *S. aureus*, was greater during disease flares than at baseline or post-treatment, and correlated with worsened disease severity. Interestingly, various AD treatments were associated with increased bacterial diversity. *S. aureus* infection may also predispose AD patients to disseminated viral skin infections.⁹¹ Control of infection generally involves appropriate use of antibiotics. It is important to treat only infections that are clinically overt as most AD patients are colonized with *S. aureus* and overuse of antibiotics can lead to MRSA infection.²² In pa-

tients prone to *S. aureus* infection, consider using bleach baths.⁹²

Pruritus is the cardinal symptom of AD that adversely impacts quality of life and makes it difficult to control the skin disease since scratching itself induces skin rashes in these patients. Improved skin barrier preventing allergen/microbial penetration and effective anti-inflammatory therapy is associated with reduced pruritus. Conventional H-1 antihistamine therapy is frequently ineffective but recent studies suggest H4 blockers may be more important in the itch of AD.⁹³ The unclear role of antihistamines in controlling itch of AD reflects the wide variety of mediators implicated in pruritus in AD.⁹⁴ IL-31, which is highly pruritic when overexpressed in animal models of AD, has also been found to be increased in AD. Irrespective of the atopic phenotype, serum IL-31 levels have been shown to correlate with disease activity in AD.⁹⁵

In AD patients who are refractory to conventional treatment approaches, a number of alternative strategies have been proposed including the use of cyclosporine, methotrexate, azathioprine, immunoadsorption, IL-6 blockade, conventional immunotherapy and ultraviolet light.⁹⁶⁻¹⁰² Vitamin D deficiency is being increasingly recognized as playing a role in allergic diseases.¹⁰³ Vitamin D appears to also have several beneficial effects in AD including the upregulation of antimicrobial peptides involved in control of infection as well as induction of T regulatory cells which can suppress inflammation.¹⁰⁴ Preliminary results of a clinical trial in children with AD treated with oral vitamin D in a randomized, controlled trial showed clinical improvement versus placebo.¹⁰⁵ Since current treatment approaches are not curative, there is considerable interest in also studying approaches to prevent AD.¹⁰⁶ The use of probiotic therapy or bacterial lysates early in the course of illness remains an area of active investigation.^{107,108}

CONCLUSIONS

Patients with AD have genetic mutations that affect their skin barrier function and immune responses triggered by unique environmental triggers. A crosstalk occurs such that the immune response can adversely impair skin barrier function in AD. Clinically, this results in intensely pruritic, inflamed skin that allows penetration of irritants and allergens and predisposes patients to colonization and infection by microbial organisms. Insights into the complex relationship between skin barrier and immune abnormalities should lead to more targeted therapy for AD and associated infectious complications. New methods to categorize distinct phenotypes and polarized immune pathways of AD may lead to novel early intervention strategies that could also interrupt the development of asthma and allergic disorders.

ACKNOWLEDGEMENTS

This work was supported by NIH/NIAID contract HHSN272201000020C and AR41256.

The author wishes to acknowledge The Edelstein Family Foundation for their generous support of his work in atopic dermatitis.

REFERENCES

- Boguniewicz M, Leung DYM. Atopic dermatitis: A disease of altered skin barrier and immune dysregulation. *Immunol Rev* 2011;**242**:233-46.
- Yaghmaie P, Koudelka CW, Simpson EL. Mental health comorbidity in patients with atopic dermatitis. *J Allergy Clin Immunol* 2013;**131**:428-33.
- Slattery MJ, Essex MJ, Paletz EM *et al*. Depression, anxiety, and dermatologic quality of life in adolescents with atopic dermatitis. *J Allergy Clin Immunol* 2011;**128**:668-71.
- Shaw TE, Currie GP, Koudelka CW, Simpson EL. Eczema prevalence in the United States: data from the 2003 National Survey of Children's Health. *J Invest Dermatol* 2011;**131**:67-73.
- Xu F, Yan S, Li F *et al*. Prevalence of childhood atopic dermatitis: an urban and rural community-based study in Shanghai, China. *PLoS One* 2012;**7**:e36174.
- Silverberg JL, Kleiman E, Lev-Tov H *et al*. Association between obesity and atopic dermatitis in childhood: A case-control study. *J Allergy Clin Immunol* 2011;**127**:1180-6.
- Roduit C, Wohlgensinger J, Frei R *et al*. Prenatal animal contact and gene expression of innate immunity receptors at birth are associated with atopic dermatitis. *J Allergy Clin Immunol* 2011;**127**:179-85.
- Caroline R, Frei R, Loss G *et al*. Development of atopic dermatitis according to age of onset and association with early-life exposures. *J Allergy Clin Immunol* 2012;**130**:130-6.
- Illi S, Depner M, Genuneit J *et al*. Protection from childhood asthma and allergy in Alpine farm environments—the GABRIEL Advanced Studies. *J Allergy Clin Immunol* 2012;**129**:1470-7.
- Niwa Y, Sumi H, Kawahira K, Terashima T, Nakamura T, Akamatsu H. Protein oxidative damage in the stratum corneum: Evidence for a link between environmental oxidants and the changing prevalence and nature of atopic dermatitis in Japan. *Br J Dermatol* 2003;**149**:248-54.
- Kodama A, Horkawa T, Suzuki T *et al*. Effect of stress on atopic dermatitis: investigation in patients after the great hanshin earthquake. *J Allergy Clin Immunol* 1999;**104**:173-6.
- Kuo I, Yoshida T, De Benedetto A, Beck LA. The cutaneous innate immune response in patients with atopic dermatitis. *J Allergy Clin Immunol* 2013;**131**:266-78.
- McAlear MA, Irvine AD. The multifunctional role of filaggrin in allergic skin disease. *J Allergy Clin Immunol* 2013;**131**:280-91.
- Schneider L, Lio P, Boguniewicz M *et al*. Atopic dermatitis: a practice parameter update 2012. *J Allergy Clin Immunol* 2013;**131**:295-9.
- Bieber T. Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and stratified medicine. *Allergy* 2012;**67**:1475-82.
- Ye YM, Kim BE, Shin YS, Park HS, Leung DYM. Overexpression of Epidermal Filaggrin in Patients with Chronic Idiopathic Urticaria Correlates with Urticaria Severity. *J Allergy Clin Immunol* 2013;**131** (Suppl):AB56.
- Reginald K, Westritschnig K, Linhart B *et al*. Staphylococcus aureus fibronectin-binding protein specifically binds IgE from patients with atopic dermatitis and requires antigen presentation for cellular immune responses. *J Allergy Clin Immunol* 2011;**128**:82-91.
- James EA, Kwok WW. Autoreactive CD4 T cells in patients with atopic dermatitis. *J Allergy Clin Immunol* 2011;**128**:100-1.
- Tang TS, Bieber T, Williams H. Does "autoreactivity" play a role in eczema? *J Allergy Clin Immunol* 2012;**129**:1209-15.
- Balaji H, Heratizadeh A, Wichmann K *et al*. Malassezia symposiumalis thioredoxin-specific T cells are highly cross-reactive to human thioredoxin in atopic dermatitis. *J Allergy Clin Immunol* 2011;**128**:92-9.
- Leung DYM, Gao PS, Grigoryev DN *et al*. Human atopic dermatitis complicated by eczema herpeticum is associated with abnormalities in IFN-g response. *J Allergy Clin Immunol* 2011;**127**:965-73.
- Boguniewicz M, Leung DYM. Recent insights into atopic dermatitis and implications for management of infectious complications. *J Allergy Clin Immunol* 2010;**125**:4-13.
- Beck LA, Boguniewicz M, Hata TR *et al*. Phenotype of atopic dermatitis subjects with a history of eczema herpeticum. *J Allergy Clin Immunol* 2009;**124**:260-9.
- Broccardo CJ, Mahaffey S, Schwarz J *et al*. Comparative proteomic profiling of patients with atopic dermatitis based on history of eczema herpeticum infection and *Staphylococcus aureus* colonization. *J Allergy Clin Immunol* 2011;**127**:186-93.
- Cork MJ, Danby SG, Vasilopoulos Y *et al*. Epidermal barrier dysfunction in atopic dermatitis. *J Invest Dermatol* 2009;**129**:1892-908.
- Nomura I, Goleva E, Howell MD *et al*. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. *J Immunol* 2003;**171**:3262-9.
- Ong PY, Ohtake T, Brandt C *et al*. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. *N Engl J Med* 2002;**347**:1151-60.
- Guttman-Yassky E, Nogales K. Contrasting pathogenesis of atopic dermatitis and psoriasis-Part I: Clinical and pathologic concepts. *J Allergy Clin Immunol* 2011;**127**:1110-8.
- Suarez-Farinas M, Tintle SJ, Shemer A *et al*. Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. *J Allergy Clin Immunol* 2011;**127**:954-64.
- Morizane S, Yamasaki K, Kajita A *et al*. TH2 cytokines increase kallikrein 7 expression and function in patients with atopic dermatitis. *J Allergy Clin Immunol* 2012;**130**:259-61.
- Zhang B, Alysandratos K, Angelidou A *et al*. Human mast cell degranulation and preformed TNF secretion require mitochondrial translocation to exocytosis sites: Relevance to atopic dermatitis. *J Allergy Clin Immunol* 2011;**127**:1522-31.
- Candi E, Schmidt R, Melino G. The cornified envelope: a model of cell death in the skin. *Nat Rev Mol Cell Biol* 2005;**6**:328-40.
- Rawlings AV, Scott IR, Harding CR, Bowser PA. Stratum corneum moisturization at the molecular level. *J Invest Dermatol* 1994;**103**:731-41.
- Irvine AD, McLean WHI, Leung DYM. Filaggrin muta-

- tions associated with skin and allergic diseases. *N Engl J Med* 2011;**365**:1315-27.
35. Elias PM, Wakefield JS. Therapeutic implications of a barrier-based pathogenesis of atopic dermatitis. *Clin Rev Allergy Immunol* 2011;**41**:282-95.
 36. Miajlovic H, Fallon PG, Irvine AD, Foster TJ. Effect of filaggrin breakdown products on growth of and protein expression by *Staphylococcus aureus*. *J Allergy Clin Immunol* 2010;**126**:1184-90.
 37. Margolis DV, Apter AJ, Gupta J *et al*. The persistence of atopic dermatitis and filaggrin (FLG) mutations in a US longitudinal cohort. *J Allergy Clin Immunol* 2012;**130**:912-7.
 38. Böhme M, Söderhäll C, Kull I, Bergström A, van Hage M, Wahlgren C. Filaggrin mutations increase the risk for persistent dry skin and eczema independent of sensitization. *J Allergy Clin Immunol* 2012;**129**:1153-5.
 39. Kawasaki H, Nagao K, Kubo A *et al*. Altered stratum corneum barrier and enhanced percutaneous immune responses in filaggrin-null mice. *J Allergy Clin Immunol* 2012;**129**:1538-46.
 40. Kezic S, O'Regan GM, Lutter R *et al*. Filaggrin loss-of-function mutations are associated with enhanced expression of IL-1 cytokines in the stratum corneum of patients with atopic dermatitis and in a murine model of filaggrin deficiency. *J Allergy Clin Immunol* 2012;**129**:1031-9.
 41. Brauweiler AM, Bin L, Kim BE *et al*. Filaggrin dependent secretion of sphingomyelinase protects against *Staphylococcal* alpha-toxin-induced keratinocyte death. *J Allergy Clin Immunol* 2013;**131**:421-7.
 42. Thyssen JP, Thuesen BH, Huth C *et al*. Skin barrier abnormality caused by filaggrin (FLG) mutations is associated with increased serum 25-hydroxy vitamin D concentrations. *J Allergy Clin Immunol* 2012;**130**:1204-7.
 43. Brown SJ, Kroboth K, Sandilands A *et al*. Intragenic copy number variation within filaggrin contributes to the risk of atopic dermatitis with a dose-dependent effect. *J Invest Dermatol* 2012;**132**:98-104.
 44. Howell MD, Kim BE, Gao P *et al*. Cytokine modulation of atopic dermatitis filaggrin skin expression. *J Allergy Clin Immunol* 2007;**120**:150-5.
 45. Kim BE, Howell MD, Guttman E *et al*. TNF-alpha downregulates filaggrin and loricrin through c-Jun N-terminal kinase: Role for TNF-alpha antagonists to improve skin barrier. *J Invest Dermatol* 2011;**131**:1272-9.
 46. Deleuran M, Hvid M, Kemp K, Christensen GB, Deleuran B, Vestergaard C. IL-25 induces both inflammation and skin barrier dysfunction in atopic dermatitis. *Chem Immunol Allergy* 2012;**96**:45-9.
 47. De Benedetto A, Rafaels NM, McGirt LY *et al*. Tight junction defects in patients with atopic dermatitis. *J Allergy Clin Immunol* 2011;**127**:773-86.
 48. Furuse M, Hata M, Furuse K *et al*. Claudin-based tight junctions are crucial for the mammalian epidermal barrier: a lesson from claudin-1-deficient mice. *J Cell Biol* 2002;**156**:1099-111.
 49. De Benedetto A, Slifka MK, Rafaels NM *et al*. Reductions in Claudin-1 may enhance susceptibility to HSV-1 infections in atopic dermatitis. *J Allergy Clin Immunol* 2011;**128**:242-6.
 50. Novak N. An update on the role of human dendritic cells in patients with atopic dermatitis. *J Allergy Clin Immunol* 2012;**129**:879-86.
 51. Gittler JK, Shemer A, Suárez-Fariñas M *et al*. Progressive activation of TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. *J Allergy Clin Immunol* 2012;**130**:1344-54.
 52. Cornelissen C, Marquardt Y, Czaja K *et al*. IL-31 regulates differentiation and filaggrin expression in human organotypic skin models. *J Allergy Clin Immunol* 2012;**129**:426-33.
 53. Rebane A, Zimmermann M, Aab A *et al*. Mechanisms of IFN- γ -induced apoptosis of human skin keratinocytes in patients with atopic dermatitis. *J Allergy Clin Immunol* 2012;**129**:1297-306.
 54. Boyman O, Werfel T, Akdis CA. The suppressive role of IL-10 in contact and atopic dermatitis. *J Allergy Clin Immunol* 2012;**129**:160-1.
 55. Girard-Madoux MJ, Kel JM, Reizis B, Clausen BE. IL-10 controls dendritic cell-induced T-cell reactivation in the skin to limit contact hypersensitivity. *J Allergy Clin Immunol* 2012;**129**:143-50.
 56. Oh SH, Park CO, Wu WH *et al*. Corticotropin-releasing hormone downregulates IL-10 production by adaptive forkhead box protein 3-negative regulatory T cells in patients with atopic dermatitis. *J Allergy Clin Immunol* 2012;**129**:151-9. e1-6.
 57. Vasiadi M, Therianou A, Sideri K *et al*. Increased serum CRH levels with decreased skin CRHR-1 gene expression in psoriasis and atopic dermatitis. *J Allergy Clin Immunol* 2012;**129**:1410-3.
 58. Krueger J, Fretzin S, Suárez-Fariñas M *et al*. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. *J Allergy Clin Immunol* 2012;**130**:145-54.
 59. Oyoshi MK, Wang JY, Geha RS. Immunization with modified vaccinia virus Ankara prevents eczema vaccinatum in a murine model of atopic dermatitis. *J Allergy Clin Immunol* 2011;**128**:890-1.
 60. Choy DF, Hsu DK, Seshasayee D *et al*. Comparative transcriptomic analyses of atopic dermatitis and psoriasis reveal shared neutrophilic inflammation. *J Allergy Clin Immunol* 2012;**130**:1335-43.
 61. Fujita H, Shemer A, Suarez-Farinas M *et al*. Lesional dendritic cells in patients with chronic atopic dermatitis and psoriasis exhibit parallel ability to activate T-cell subsets. *J Allergy Clin Immunol* 2011;**128**:574-82.
 62. Gros E, Petzold S, Maintz L, Bieber T, Novak N. Reduced IFN- γ receptor expression and attenuated IFN- γ response by dendritic cells in patients with atopic dermatitis. *J Allergy Clin Immunol* 2011;**128**:1015-21.
 63. Vanbervliet B, Akdis M, Vocanson M, Rozieres A, Benetiere J, Rouzair P. Histamine receptor H1 signaling on dendritic cells plays a key role in the IFN- γ /IL-17 balance in T cell-mediated skin inflammation. *J Allergy Clin Immunol* 2011;**127**:943-53.
 64. Ziegler SF. Thymic stromal lymphopoietin and allergic disease. *J Allergy Clin Immunol* 2012;**130**:845-52.
 65. Nakajima S, Igyártó BZ, Honda T *et al*. Langerhans cells are critical in epicutaneous sensitization with protein antigen via thymic stromal lymphopoietin receptor signaling. *J Allergy Clin Immunol* 2012;**129**:1048-55.
 66. Schmitz J, Owyang A, Oldham E *et al*. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. *Immunity* 2005;**23**:479-90.
 67. Oyoshi MK, Larson RP, Ziegler SF, Geha RS. Mechanical injury polarizes skin dendritic cells to elicit a T(H)2 response by inducing cutaneous thymic stromal lymphopoietin expression. *J Allergy Clin Immunol* 2010;**126**:976-84.
 68. Savinko T, Matikainen S, Saarialho-Kere U *et al*. IL-33 and

- ST2 in atopic dermatitis: expression profiles and modulation by triggering factors. *J Invest Dermatol* 2012;**132**:1392-400.
69. Jensen JM, Pfeiffer S, Witt M *et al*. Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis. *J Allergy Clin Immunol* 2009;**123**:1124-33.
 70. Lötvall J, Akdis CA, Bacharier LB *et al*. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. *J Allergy Clin Immunol* 2011;**127**:355-60.
 71. Williams HC, Strachan DP. The natural history of childhood eczema: observations from the British 1958 birth cohort study. *Br J Dermatol* 1998;**139**:834-9.
 72. Bannister MJ, Freeman S. Adult-onset atopic dermatitis. *Australas J Dermatol* 2000;**41**:225-8.
 73. Barker JN, Palmer CN, Zhao Y *et al*. Null mutations in the filaggrin gene (FLG) determine major susceptibility to early-onset atopic dermatitis that persists into adulthood. *J Invest Dermatol* 2007;**127**:564-7.
 74. Brown SJ, Asai Y, Cordell HJ *et al*. Loss-of-function variants in the filaggrin gene are a significant risk factor for peanut allergy. *J Allergy Clin Immunol* 2011;**127**:661-7.
 75. McLean WH, Palmer CN, Henderson J, Kabesch M, Weidinger S, Irvine AD. Filaggrin variants confer susceptibility to asthma. *J Allergy Clin Immunol* 2008;**121**:1294-5.
 76. Barnes KC. An update on the genetics of atopic dermatitis: scratching the surface in 2009. *J Allergy Clin Immunol* 2010;**125**:16-29.
 77. Dizier MH, Margaritte-Jeannin P, Madore A *et al*. The ANO3/MUC15 locus is associated with eczema in families ascertained through asthma. *J Allergy Clin Immunol* 2012;**129**:1547-53.
 78. Raedler D, Illi S, Pinto LA *et al*. IL10 polymorphisms influence neonatal immune responses, atopic dermatitis, and wheeze at age 3 years. *J Allergy Clin Immunol* 2012;**131**:789-96.
 79. Kabesch M, Carr D, Weiland SK, von Mutius E. Association between polymorphisms in serine protease inhibitor, kazal type 5 and asthma phenotypes in a large German population sample. *Clin Exp Allergy* 2004;**34**:340-5.
 80. Briot A, Deraison C, Lacroix M *et al*. Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome. *J Exp Med* 2009;**206**:1135-47.
 81. Ahmad-Nejad P, Mrabet-Dahbi S, Breuer K *et al*. The toll-like receptor 2 R753Q polymorphism defines a subgroup of patients with atopic dermatitis having severe phenotype. *J Allergy Clin Immunol* 2004;**113**:565-7.
 82. Gao PS, Rafaels NM, Mu D *et al*. Genetic variants in thymic stromal lymphopoietin are associated with atopic dermatitis and eczema herpeticum. *J Allergy Clin Immunol* 2010;**125**:1403-7.
 83. Kayserova J, Sismova K, Zentsova-Jaresova I *et al*. A prospective study in children with a severe form of atopic dermatitis: clinical outcome in relation to cytokine gene polymorphisms. *J Investig Allergol Clin Immunol* 2012;**22**:92-101.
 84. Lesiak A, Kuna P, Zakrzewski M *et al*. Combined occurrence of filaggrin mutations and IL-10 or IL-13 polymorphisms predisposes to atopic dermatitis. *Exp Dermatol* 2011;**20**:491-5.
 85. Howell MD, Gao PS, Kim BE *et al*. The signal transducer and activator of transcription 6 gene (STAT6) increases propensity of patient with atopic dermatitis patients toward disseminated viral skin infections. *J Allergy Clin Immunol* 2011;**128**:1006-14.
 86. Schulz F, Marenholz I, Fölster-Holst R *et al*. A common haplotype of the IL-31 gene influencing gene expression is associated with nonatopic eczema. *J Allergy Clin Immunol* 2007;**120**:1097-102.
 87. Novak N, Allam J-P, Bieber T. Allergic hyperreactivity to microbial components: A trigger factor of "intrinsic" atopic dermatitis? *J Allergy Clin Immunol* 2003;**112**:215-6.
 88. Schmitt J, von Kobyletzki L, Svensson A, Apfelbacher C. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials. *Br J Dermatol* 2011;**164**:415-28.
 89. van den Bogaard EH, Bergboer JGM, Vonk-Bergers M *et al*. Coal tar induces AHR-dependent skin barrier repair in atopic dermatitis. *J Clin Invest* 2013;**123**:917-27.
 90. Kong HH, Oh J, Deming C *et al*. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. *Genome Res* 2012;**22**:850-9.
 91. Bin L, Kim BE, Brauweiler A *et al*. Staphylococcus aureus a-toxin modulates skin host response to viral infection. *J Allergy Clin Immunol* 2012;**130**:683-91.
 92. Huang JT, Abrams M, Tlougan B, Rademaker A, Paller AS. Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. *Pediatrics* 2009;**123**:e808-14.
 93. Mommert S, Gschwandtner M, Gutzmer R, Werfel T. The role of the histamine H4 receptor in atopic dermatitis. *Curr Allergy Asthma Rep* 2011;**11**:21-8.
 94. Murota H, Izumi M, Abd El-Latif MI *et al*. Artemin causes hypersensitivity to warm sensation, mimicking warmth-provoked pruritus in atopic dermatitis. *J Allergy Clin Immunol* 2012;**130**:671-82.
 95. Raap U, Wichmann K, Bruder M *et al*. Correlation of IL-31 serum levels with severity of atopic dermatitis. *J Allergy Clin Immunol* 2008;**122**:421-3.
 96. Guttman-Yassky E, Nograles KE, Krueger JG. Contrasting pathogenesis of atopic dermatitis and psoriasis—Part II: Immune cell subsets and therapeutic concepts. *J Allergy Clin Immunol* 2011;**127**:1420-32.
 97. Tintle S, Shemer A, Suarez-Farinas M *et al*. Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. *J Allergy Clin Immunol* 2011;**128**:583-93.
 98. Milliken SVI, Wassall H, Lewis BJ *et al*. Effects of ultraviolet light on human serum 25-hydroxyvitamin D and systemic immune function. *J Allergy Clin Immunol* 2012;**129**:1554-61.
 99. Schram ME, Roekevisch E, Leeflang MMG, Bos JD, Schmitt J, Spuls PI. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. *J Allergy Clin Immunol* 2011;**128**:353-9.
 100. Kasperkiewicz M, Schmidt M, Frambach Y *et al*. Improvement of treatment-refractory atopic dermatitis by immunoadsorption: A pilot study. *J Allergy Clin Immunol* 2011;**127**:267-70, 270.e1-6.
 101. Navarini AA, French LE, Hofbauer GFL. Interrupting IL-6-receptor signaling improves atopic dermatitis but associates with bacterial superinfection. *J Allergy Clin Immunol* 2011;**128**:1128-30.
 102. Novak N, Bieber T, Hoffmann M *et al*. Efficacy and safety of subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. *J Allergy Clin Immunol* 2012;**130**:925-31.

- 103.** Muehleisen B, Gallo R. Vitamin D in allergic disease: Shedding light on a complex problem. *J Allergy Clin Immunol* 2013;**131**:324-9.
- 104.** Van der Aar AMG, Sibiryak DS, Bakdash G *et al.* Vitamin D3 targets epidermal and dermal dendritic cells for induction of distinct regulatory T cells. *J Allergy Clin Immunol* 2011;**127**:1532-40.
- 105.** Sidbury R, Sullivan AF, Thadhani RI, Camargo CA Jr. Randomized controlled trial of vitamin D supplementation for winter-related atopic dermatitis in Boston: a pilot study. *Br J Dermatol* 2008;**159**:245-7.
- 106.** Simpson EL, Keck LE, Chalmers JR, Williams HC. How should an incident case of atopic dermatitis be defined? A systematic review of primary prevention studies. *J Allergy Clin Immunol* 2012;**130**:137-44.
- 107.** Jensen MP, Meldrum S, Taylor AL, Dunstan JA, Prescott SL. Early probiotic supplementation for allergy prevention: Long term outcomes. *J Allergy Clin Immunol* 2012;**130**:1209-11.
- 108.** Lau S, Gerhold K, Zimmermann K *et al.* Oral application of bacterial lysate in infancy decreases the risk of atopic dermatitis in children with 1 atopic parent in a randomized, placebo-controlled trial. *J Allergy Clin Immunol* 2012;**129**:1040-7.